The global anti-hypertensive drugs market was estimated at USD 23.59 billion in 2022 and it is expected to surpass around USD 34.72 billion by 2032, poised to grow at a CAGR of 3.94% from 2023 to 2032.
Key Pointers
- North America accounted for the largest revenue share of 38% in 2022
- Asia Pacific is estimated to grow at the fastest CAGR during the forecast period.
- By Drug Class, the calcium channel blockers (CCB) segment held the largest market share of 27% in 2022.
- By Drug Class, the ACE inhibitors segment is expected to grow at the fastest CAGR of 4.98% over the forecast period.
- By Type, the primary hypertension segment held the highest market share of 72% in 2022.
- By Type, the secondary hypertension segment is expected to grow with a significant CAGR of 4.38% over the forecast period.
- By Route of Administration, the oral segment contributed the largest market share of 76% in 2022.
- By Distribution Channel, the hospital pharmacy segment accounted for the largest market share of 54% in 2022.
The anti-hypertensive drugs market plays a pivotal role in addressing the global health challenge posed by hypertension, a prevalent condition characterized by elevated blood pressure levels. This overview provides insights into the key facets shaping the market, including market dynamics, major players, therapeutic classes, and notable trends.
Market Growth
The growth of the anti-hypertensive drugs market is propelled by several key factors. Firstly, the escalating global prevalence of hypertension, exacerbated by lifestyle changes and an aging population, serves as a primary driver for market expansion. Additionally, ongoing advancements in pharmaceutical research and development contribute to the discovery of innovative drugs, fostering increased efficacy and minimized side effects. Government initiatives promoting healthcare awareness and increased expenditure further create a conducive environment for market growth. The evolving trend towards personalized medicine, tailoring treatment approaches to individual patient profiles, and the increasing adoption of combination therapies to enhance efficacy represent significant factors shaping the trajectory of the anti-hypertensive drugs market. As digital health solutions become integrated for monitoring and managing hypertension, the market is poised for sustained growth, driven by a comprehensive approach to addressing the complex and widespread health challenge posed by elevated blood pressure levels.
Get a Sample: https://www.visionresearchreports.com/anti-hypertensive-drugs-market/41039
Report Scope of the Anti-hypertensive Drugs Market
| Report Coverage | Details |
| Market Revenue by 2032 | USD 34.72 billion |
| Growth Rate from 2023 to 2032 | CAGR of 3.94% |
| Revenue Share of North America in 2022 | 38% |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
Market Dynamics
Drivers
- Rising Global Incidence of Hypertension: The primary driver for the growth of the anti-hypertensive drugs market is the increasing prevalence of hypertension on a global scale. Factors such as sedentary lifestyles, dietary habits, and an aging population contribute to the escalating numbers of individuals diagnosed with high blood pressure.
- Technological Advancements in Drug Development: Ongoing advancements in pharmaceutical research and development play a crucial role in driving market growth. The discovery of innovative anti-hypertensive drugs with enhanced efficacy and reduced side effects contributes to the expansion of treatment options for healthcare providers and patients.
Restraints
- Adverse Effects and Tolerability Issues: A significant restraint in the anti-hypertensive drugs market is the presence of adverse effects associated with certain medications. Patient tolerance and potential side effects, ranging from mild discomfort to more severe complications, can impact medication adherence and pose challenges for both patients and healthcare providers.
- Stringent Regulatory Approvals and Compliance Standards: The stringent regulatory approval processes for new anti-hypertensive drugs can act as a restraint. Compliance with rigorous standards may extend the time and resources required for drug development, hindering the timely introduction of innovative solutions to the market.
Opportunities
- Focus on Precision Medicine: The industry’s emphasis on precision medicine provides an avenue for growth. Tailoring anti-hypertensive treatments based on genetic factors and individual patient characteristics can enhance treatment efficacy and patient outcomes, aligning with the trend towards personalized healthcare.
- Technological Integration for Monitoring: The integration of technology for monitoring and managing hypertension represents a promising opportunity. Digital health solutions, including wearable devices and mobile applications, offer innovative ways to track patient data, improve medication adherence, and enhance overall disease management.
Drug Class Insights
Calcium channel blockers (CCB) segment held the largest market share of 27% in 2022 owing to lesser side effects exhibited by these drugs compared to other anti-hypertensive drugs. Moreover, long-acting CCBs provide more consistent blood pressure control throughout the day and require less frequent dosing. Their efficacy, safety profile, diverse options, and suitability for combination therapy make CCD a vital component of hypertension management. These factors are contributing to the large share of the market.
ACE inhibitors segment is expected to grow at the fastest CAGR of 4.98% over the forecast period. The rising prevalence of high blood pressure and increasing prescription of these drugs for cardiovascular diseases & other chronic conditions are major drivers for the segment growth. Moreover, availability of generic forms makes it a cost-effective option for hypertension management, which is anticipated to increase the prescription rate over the projected years.
Type Insights
Primary hypertension segment held the highest market share of 72% in 2022. It is the most common type of hypertension and accounts for majority of cases. According to the National Ambulatory Medical Care Survey 2019, in the U.S. medical records, 33.2% of patients visit physician offices due to primary hypertension. Growing number of cases of essential hypertension, driven by factors such as lifestyle choices, an aging population, improved detection, and effective treatment guidelines, contributes to the expansion of the market.
Secondary hypertension segment is expected to grow with a significant CAGR of 4.38% over the forecast period attributed to increasing prevalence of underlying medical conditions such as kidney disease & hormonal disorders, improved diagnosis of secondary hypertension, and development of new anti-hypertensive drugs. Moreover, major pharmaceutical companies are investing in developing new anti-hypertensive drugs for secondary hypertension through various strategies such as collaborations, new product launches, mergers, and acquisitions.
Route of Administration Insights
Oral segment contributed the largest market share of 76% in 2022 and is expected to grow at the fastest CAGR. This growth is attributed to increased patient preference for oral medications and growing demand for fixed-dose combinations of anti-hypertensive drugs. Pharmaceutical companies constantly develop new oral anti-hypertensive drugs with improved efficacy and safety profiles. This is also driving the growth of the market’s oral route of administration segment. In April 2021, the FDA approved Macitentan Tablets, 10 mg of Zydus Worldwide DMCC. These tablets are used to treat pulmonary arterial hypertension and reduce the risks of disease progression.
Injectables segment held the second-largest share of the market. Injectable anti-hypertensive drugs are a crucial component of the treatment in cases of hypertensive emergencies, where rapid and precise blood pressure reduction is necessary. Moreover, increasing hospitalization due to life-threatening diseases and chronic conditions, such as heart attacks, strokes, and kidney disease, is expected to increase the demand for injectable drugs.
Distribution Channel Insights
Hospital pharmacy segment accounted for the largest market share of 54% in 2022. This can be attributed to increase in the number of hospitalizations due to high blood pressure and other chronic diseases. Additionally, anti-hypertensive drugs are prescription-based medications prescribed by specialized healthcare professionals who are available in hospital settings, contributing to segment’s growth. A doctor’s prescription enables healthcare professionals to assess the patient’s overall health and medication regimen to minimize risks and manage any potential side effects or drug interactions. It is expected to fuel the demand for anti-hypertensive drugs in the hospital pharmacy segment.
Online pharmacy segment is expected to grow at the fastest CAGR during the projected timeframe attributed to increasing convenience, affordability, and privacy that online pharmacies offer to patients. Moreover, government bodies are ensuring that patients have access to the medications they need to manage their hypertension. For instance, in November 2019, the National Health Service (NHS) Digital Pharmacy Program UK introduced the Electronic Prescription Service (EPS). The EPS makes it easier for patients to obtain anti-hypertensive and other drugs.
Regional Insights
North America accounted for the largest revenue share of 38% in 2022 owing to the availability of anti-hypertensive drugs and development of new and more effective anti-hypertensive drugs. Moreover, surge in the incidence of hypertension and rise in obesity significantly contribute to the growth of the market in the region. According to Centers for Disease Control and Prevention, obesity in the U.S. affects 100.1 million people in 2023, with adults 41.9% and 19.7% of children. These factors are contributing to the significant share of the region.
Asia Pacific is estimated to grow at the fastest CAGR during the forecast period. Increasing prevalence of hypertension in Asia Pacific region is a major driver for the market. As the population ages and lifestyles change, incidence of hypertension is rising. Excessive salt consumption is a significant contributor to the prevalence of hypertension in the Asia Pacific region. According to the WHO, China consumes excessive salt in food, an average of 9.3 grams per day in home cooking, which is approximately double as compared to the recommended amount. More than 27.5% of Chinese adults have high blood pressure and cardiovascular disease. These factors are expected to drive the regional market growth.
Key Companies
- Sanofi
- Boehringer Ingelheim International GmbH
- Novartis AG
- Johnson & Johnson Services, Inc.
- DAIICHI SANKYO COMPANY, LIMITED.
- Merck & Co., Inc.
- AstraZeneca
- Pfizer Inc.
- Lupin
- Sun Pharmaceutical Industries Ltd.
Anti-hypertensive Drugs Market Report Segmentations:
By Drug Class
- Diuretics
- ACE Inhibitors
- Calcium Channel Blockers
- Beta-adrenergic Blockers
- Vasodilators
- Others
By Type
- Primary Hypertension
- Secondary Hypertension
By Route of Administration
- Oral
- Injectables
- Others
By Distribution Channel
- Retail Pharmacy
- Hospital Pharmacy
- Online Pharmacy
By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Buy this Premium Research Report@ https://www.visionresearchreports.com/report/checkout/41039
You can place an order or ask any questions, please feel free to contact sales@visionresearchreports.com| +1 650-460-3308